5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group.
Clavel
M
M
Centre Léon Bérard, Lyon, France.
Monfardini
S
S
Fosså
S
S
Smyth
J
J
Renard
J
J
Kaye
S B
SB
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001374:Azacitidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077209:Decitabine; D004341:Drug Evaluation; D004407:Dysgerminoma / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013736:Testicular Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D000077209:Decitabine; D001374:Azacitidine